Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kelyniam Global, Inc. (KLYG)
Collinsville, CT, US
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-grade polymers. Additionally, Kelyniam develops, produces, and supplies specific cranial and craniofacial fixation screws, crucial for the reconstruction of skull and facial structures. Its clientele encompasses health systems, hospitals, sales representatives, surgeons, insurance providers (payors), and individual patients. Established in 2005, the company was originally named Ketner Global Investments, Inc., rebranding to Kelyniam Global, Inc. in December 2007. Kelyniam Global is based in Collinsville, Connecticut.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.49% | +0.15% | +0.00% | +18.18% | +4.00% | +11.59% | -7.14% | +62.50% | -7.14% | +188.89% | -5.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%-8.3% Q1'26: +84.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+84.9% ★ Q1'26: +63.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-8.6% Q1'26: +15.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-3.5% Q1'26: +25.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-8.9% Q1'26: +119.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.7% Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-8.60× Q1'26: 0.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ketner | 3.90M | 90.00% | 3.90M | — | 3.90M | 10.00 | IN | States | 2007-04-19 | ↗ |
| 2 | LynRay | 280.0K | 6.00% | 280.0K | — | 280.0K | — | IN | States | 2007-10-25 | ↗ |
| 3 | Mastoloni | 235.0K | 5.00% | 235.0K | — | 235.0K | — | IN | States | 2007-11-29 | ↗ |
| 4 | Borges dos Santos | 10.0K | 1.00% | 10.0K | — | 10.0K | 10.00 | IN | States | 2007-04-19 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-06-25 | Ketner James | Director / Officer / 10% Owner | J-Other | D | Common Stock | 500,000 | 0.00 | — | 7,544,800 | — | ↗ |
| 2008-04-07 | Ketner James | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 4,800 | 0.54 | 2.6K | 7,809,800 | — | ↗ |
| 2008-04-03 | Ketner James | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.45 | 2.3K | 7,805,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Mirucki | Chief Medical Officer | — | — |
| Desiree Webb | Chief Operating and Revenue Officer | — | female |
| James Barrow | General Counsel and Director of Quality & Regulatory | — | male |
| Michael Hamblett | Director of Investor Relations | — | — |
| Ross Bjella | Chairman & Chief Executive Officer | — | male |
| Terrance Kurtenbach | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KLYG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
